Dr. Richard Furman Discusses Emerging Strategies for the Treatment of CLL & Follicular Lymphoma

In this video from Onc Live, Dr. Richard Furman, Director of the CLL Research Center discusses emerging strategies in the treatment of CLL and follicular lymphoma, specifically citing the use of venetoclax also known as ABT-199.

For patients with CLL the following trials are open to accrual.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s